Study of Fluoxetine in Adults With Autistic Disorder
Completed · Not applicable
Conditions studied: Autistic Disorder
In brief
This is a study to determine the effect of fluoxetine in the treatment of adult autism and on functional ability and behavior associated with autism. Evidence suggests abnormal serotonin function in autism. Fluoxetine is a selective inhibitor of the serotonin transporter.
Key facts
- Study ID
- NCT00027404
- Run by
- Icahn School of Medicine at Mount Sinai
- People needed
- 48
- Starts
- 2001-09-01
- Expected to finish
- 2005-08-01
- Last updated by the study team
- 2015-03-25
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Meets DSM-IV and ADI criteria for autistic disorder
- Patients must use effective contraception
- Negative pregnancy test
- Clinical Global Impression-Severity Scale for Autistic Disorder (CGI-AD) score of 4
You may not qualify if…
- Pregnant or nursing
- Prior or concurrent history of mental disorders, including schizophrenia, schizoaffective disorder, organic mental disorders, or bipolar disorders
- Concurrent depression determined by DSM-IV diagnosis
- Serious suicidal risk
- Active seizure disorder within the past 2 years
- Clinically significant or unstable medical illness, including hematopoietic or cardiovascular disease
- Any organic or systemic disease
- Any geographical condition that would preclude study compliance
- Prior or concurrent gastrointestinal, liver, or kidney disease
- Any other concurrent condition that interferes with the absorption, distribution, metabolism, or excretion of drugs
- Prior or concurrent cerebrovascular disease or brain trauma
- Prior or concurrent clinically significant unstable endocrine disorder, such as hypo- or hyperthyroidism
- Prior or concurrent malignancy
- Clinically significant abnormalities on EKG, laboratory tests, or physical exam
- Requirement for ECT or any other psychotropic medication
- Inability to tolerate taper from psychoactive medication
- History of hypersensitivity or severe side effects associated with the use of fluoxitine or other serotonin reuptake inhibitors
- Treatment with any drug known to have a well-defined potential for toxicity to a major organ within the past 30 days
- Concurrent terfenadine (Seldane) or astemizole (Hismanal)
- Prior treatment with fluoxetine of 40 mg/day for 6 weeks
- Prior electroconvulsive therapy within the past 3 months
- Prior investigational drug use within the past 30 days
- Prior Monoamine oxidase inhibitor use within the past 14 days
- Prior long-acting phenothiazines within the past 6 weeks
- Prior psychotropic drugs within the past 7 days
Where it is running
- Mount Sinai School of Medicine — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.